Grant: Proof of Principle Program - Phase I
Université Laval
$160,000.00
Cells lines for screening GPCR/Nav signaling compound
EF 2012-13
Résumé
The focus of research covered in this Proof Of Principal - Phase I application is the generation and validation of new cellular models that will be used for drug discovery. These new transgenic cell lines will be the cornerstones for the further development and commercialization of rapid screenning protocols of chemical libraries (hundreds of thousand compounds). We previously discovered that the physical association of a dopamine receptor with a membrane channel having specificity to sodium ions shift all the signaling output of the receptor toward molecules that have been shown to be targeted by mood stabilizers, and thus important for behaviors regulation. To date, this cellular model is unique, and will be usefull for identification and selection of new highly selective molecules with minimal unwanted side effects for the treatment of depression, dipolar disorder and schyzophrenia. We are now interested in the development of other cellular models expressing different membrane receptors and sodium channels. Seven different cell lines will be develop, each one containing a receptor specific to neurotransmitters dopamine or serotonin along with one of the three ionic channels studied, all specific to sodium ions. These cell lines will be first tested for confirmation of the signaling mechanism modulation. Our second objective will be to validate the use of these cellular models with technologies that allowed a researcher to quickly conduct millions of chemical, genetic or pharmacological tests, named high throughput screening (HTS). Two HTS technologies were selected, the AlphaScreen SureFire will allow us to easily monitored the receptor activity, thus confirming or not the shift of the signaling output of the receptor. The second technology is the Bioluminescence Energy Transfer (BRET) will allow the possibility to identify new compounds that disturb the physical interaction between the receptor and the channel.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
282915
Name
Beaulieu Martin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Cells lines for screening GPCR/Nav signaling compound
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Drug Screening; Gpcr Arrestin Mediated Signaling; Voltage Gated Sodium Channels
Abstract
The focus of research covered in this Proof Of Principal - Phase I application is the generation and validation of new cellular models that will be used for drug discovery. These new transgenic cell lines will be the cornerstones for the further development and commercialization of rapid screenning protocols of chemical libraries (hundreds of thousand compounds). We previously discovered that the physical association of a dopamine receptor with a membrane channel having specificity to sodium ions shift all the signaling output of the receptor toward molecules that have been shown to be targeted by mood stabilizers, and thus important for behaviors regulation. To date, this cellular model is unique, and will be usefull for identification and selection of new highly selective molecules with minimal unwanted side effects for the treatment of depression, dipolar disorder and schyzophrenia. We are now interested in the development of other cellular models expressing different membrane receptors and sodium channels. Seven different cell lines will be develop, each one containing a receptor specific to neurotransmitters dopamine or serotonin along with one of the three ionic channels studied, all specific to sodium ions. These cell lines will be first tested for confirmation of the signaling mechanism modulation. Our second objective will be to validate the use of these cellular models with technologies that allowed a researcher to quickly conduct millions of chemical, genetic or pharmacological tests, named high throughput screening (HTS). Two HTS technologies were selected, the AlphaScreen SureFire will allow us to easily monitored the receptor activity, thus confirming or not the shift of the signaling output of the receptor. The second technology is the Bioluminescence Energy Transfer (BRET) will allow the possibility to identify new compounds that disturb the physical interaction between the receptor and the channel.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beaulieu, Martin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~